EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Effect on neutrophil migration and antimicrobial functions by the Bruton's tyrosine kinase inhibitors tolebrutinib, evobrutinib, and fenebrutinib

Mirre De Bondt, Janne Renders, Paloma Petit de Prado, Nele Berghmans, Noëmie Pörtner, Lotte Vanbrabant, Vívian Louise Soares de Oliveira, Gayel Duran, Paulien Baeten, Bieke Broux, Mieke Gouwy, Patrick Matthys iD und 2 weitere

Journal of Leukocyte Biology · 14.03.2025 · 117 (3)

DOI: 10.1093/jleuko/qiae160 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Leukocyte Biology, online erschienen am 08.07.2024. Verfasst von Mirre De Bondt und 13 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Molecular Immunology, Department of Microbiology, Immunology and Transplantation, Rega Institute for Medical Research, KU Leuven, Heres…. Hauptthemen laut MEDLINE: Neutrophils, Agammaglobulinaemia Tyrosine Kinase, Protein Kinase Inhibitors, Piperidines. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Research Foundation of Flanders, Bijzonder Onderzoeksfonds, Charcot Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Multiple sclerosis (MS) is a neurodegenerative, autoimmune disease that is still incurable. Nowadays, a variety of new drugs are being developed to prevent excessive inflammation and halt neurodegeneration. Among these are the inhibitors of Bruton's tyrosine kinase (BTK). Being indispensable for B cells, this enzyme became an appealing therapeutic target for autoimmune diseases. Recognizing the emerging importance of BTK in myeloid cells, we investigated the impact of upcoming BTK inhibitors on neutrophil functions. Although adaptive immunity in MS has been thoroughly studied, unanswered questions about the pathogenesis can be addressed by studying the effects of candidate MS drugs on innate immune cells such as neutrophils, previously overlooked in MS. In this study, we used 3 BTK inhibitors (evobrutinib, fenebrutinib, and tolebrutinib), and found that they reduce neutrophil activation by the bacterial peptide fMLF and the chemokine interleukin-8/CXCL8. Furthermore, they diminished the production of reactive oxygen species and release of neutrophil extracellular traps. Additionally, the production of CXCL8 and interleukin-1β in response to inflammatory stimuli was decreased. Inhibitory effects of the drugs on neutrophil activation were not related to toxicity. Instead, BTK inhibitors prolonged neutrophil survival in an inflammatory environment. Finally, treatment with BTK inhibitors decreased neutrophil migration toward CXCL8 in a Boyden chamber assay but not in a transendothelial setup. Also, in vivo CXCL1-induced migration was unaffected by BTK inhibitors. Collectively, this study provides novel insights into the impact of BTK inhibitors on neutrophil functions, thereby holding important implications for autoimmune or hematological diseases in which BTK is crucial.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeutrophilsAgammaglobulinaemia Tyrosine KinaseProtein Kinase InhibitorsPiperidinesCell MovementPyrazolesPyrazinesHumansReactive Oxygen SpeciesInterleukin-8Extracellular TrapsNeutrophil ActivationPyrimidinesNitrilesInterleukin-1betaTyrosine Kinase InhibitorsPiperazinesPyridones

Stichwörter der Autor:innen

Bruton’s tyrosine kinase signalingautoimmunityinnate immunitypharmacological inhibitors

Substanzen

Agammaglobulinaemia Tyrosine KinaseProtein Kinase InhibitorsevobrutinibfenebrutinibPiperidinesReactive Oxygen SpeciesInterleukin-8BTK protein, humanPyrimidinesNitriles

Autor:innen und Institutionen

  • Laboratory of Molecular Immunology, Department of Microbiology, Immunology and Transplantation, Rega Institute for Medical Research, KU Leuven, Herestraat 49, 3000 Leuven, Belgium.
  • Neuro Immune Connections & Repair Lab, Department of Immunology and Infection, Biomedical Research Institute, Hasselt University, Agoralaan C, 3500 Hasselt, Belgium.
  • University MS Center, Pelt-Hasselt, Agoralaan gebouw D, 3590 Hasselt, Belgium.
  • Laboratory of Immunobiology, Department of Microbiology, Immunology and Transplantation, Rega Institute for Medical Research, KU Leuven, Herestraat 49, 3000 Leuven, Belgium.

ORCID-Profile: Patrick Matthys, Sofie Struyf

Förderung

  • Research Foundation of Flanders
  • Bijzonder Onderzoeksfonds
  • Charcot Foundation
  • Rega Foundation

Zitieren

APA

De Bondt, M., Renders, J., Petit de Prado, P., Berghmans, N., Pörtner, N., Vanbrabant, L., de Oliveira, V. L. S., Duran, G., Baeten, P., Broux, B., Gouwy, M., Matthys, P., Hellings, N., & Struyf, S. (2025). Effect on neutrophil migration and antimicrobial functions by the Bruton's tyrosine kinase inhibitors tolebrutinib, evobrutinib, and fenebrutinib. Journal of Leukocyte Biology, 117(3). https://doi.org/10.1093/jleuko/qiae160

Vancouver

De Bondt M, Renders J, Petit de Prado P, Berghmans N, Pörtner N, Vanbrabant L, et al. Effect on neutrophil migration and antimicrobial functions by the Bruton's tyrosine kinase inhibitors tolebrutinib, evobrutinib, and fenebrutinib. Journal of Leukocyte Biology. 2025;117(3). doi:10.1093/jleuko/qiae160

BibTeX
@article{DeBondt2025,
  author = {De Bondt, Mirre and Renders, Janne and Petit de Prado, Paloma and Berghmans, Nele and Pörtner, Noëmie and Vanbrabant, Lotte and de Oliveira, Vívian Louise Soares and Duran, Gayel and Baeten, Paulien and Broux, Bieke and Gouwy, Mieke and Matthys, Patrick and Hellings, Niels and Struyf, Sofie},
  title = {Effect on neutrophil migration and antimicrobial functions by the Bruton's tyrosine kinase inhibitors tolebrutinib, evobrutinib, and fenebrutinib},
  journal = {Journal of Leukocyte Biology},
  year = {2025},
  volume = {117},
  number = {3},
  doi = {10.1093/jleuko/qiae160}
}
Kostenlos starten →